Background {#Sec1}
==========

Among kidney transplant recipients (KTRs), non-adherence to immunosuppressive medications is a major cause of antibody-mediated rejection, which leads to graft loss \[[@CR1], [@CR2]\]. Immunosuppressant non-adherence also contributes to the increased healthcare costs \[[@CR3]\] associated with acute rejection treatment, additional hospitalization, and re-dialysis. Therefore, it is crucial to monitor KTRs who require long-term pharmacotherapy, and prevent non-adherence.

Previous studies have reported that approximately 14--36% KTRs are non-adherent to immunosuppressive medications \[[@CR4]--[@CR6]\]. Medication non-adherence can be either intentional or unintentional. We hypothesized that unintentional forgetfulness regarding immunosuppressive medications in KTRs could be improved by continuous electronic monitoring of adherence, and by providing patients with reminder alarms from the information and communication technology (ICT)-based centralized monitoring system. Previous studies have attempted to improve medication adherence among KTRs by using technology-based adherence-promoting interventions \[[@CR7]--[@CR9]\]. Compared to prior investigations, the main methodologic difference in our present study is that we provided real-time alarms about both drug dose and interval, and used a smart pill box to determine adherence, including dose-taking adherence, dose-frequency adherence, frequency, and dose-interval adherence.

In the present study, we aimed to determine the efficacy and stability of an ICT-based centralized monitoring system with regards to improving adherence to immunosuppressive medication and transplant outcomes in KTRs.

Methods {#Sec2}
=======

Study overview {#Sec3}
--------------

Details about the study protocol have been previously described \[[@CR10]\]. Briefly, 114 KTRs who completed the informed consent form were registered and randomly assigned in a 1:1 ratio to the ICT-based centralized clinical trial monitoring group or the ambulatory follow-up group. The planned follow-up duration was 6 months. After randomization, both groups were scheduled to for 6 visits: at 4, 8, 12, 16, 20, and 24 weeks. In the ICT-based centralized clinical trial monitoring group, both patients and the medical staff received feedback in the form of texts and pill box alarms in the event of a dosage/dosing time error or a missed dose.

Feedback algorithms {#Sec4}
-------------------

In the ICT-based centralized monitoring group, both participants and medical staff received feedback in the form of text message alarms regarding missed doses, misuse, or overuse of the medication. In the event of a missed immunosuppressant dose, the first violation generates feedback within 1 h at the break of the ±3 h range from the fixed dosing time. If the dose is still not taken after the feedback, up to two additional texts are sent at a 30-min interval. Feedback was also sent within 1 h from the moment of recognition in the event of any discrepancy between the dosage taken and the dosage prescribed, and if a dose was taken outside of the allowed ±3 h dosing time range.

Hypothesis and limitations {#Sec5}
--------------------------

We hypothesized that patients failed to take their medications due to unintentional forgetfulness, and that the ICT-based centralized monitoring system could improve medication adherence among KTRs. Notably, this system does not include a camera to record patients at the moment of medication ingestion and, therefore, cannot improve intentional non-adherence.

Patient selection {#Sec6}
-----------------

The patient inclusion criteria were as follows: age of ≥8 years; underwent kidney transplantation ≥1 month ago; maintained stable renal function after kidney transplantation, with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73 m^2^; history of kidney transplantation only, with no other organ transplantations; use of tacrolimus, mycophenolic acid, and steroids for post-transplant immunosuppression; signed the informed consent form in compliance with due process; and capable of making office visits and participating in the trial in accordance with the protocol.

The patient exclusion criteria were as follows: refusal of the ICT-based centralized home monitoring; history of treatment for acute rejection within the past 3 months; active infectious disease; uncorrected ischemic heart disease; visual or auditory impairments that could affect use of the smart pill box; inability to provide fingerprint authentication of personal identity (e.g., due to adermatoglyphia); illiteracy; lack of smartphone and unable to receive text messages; and other investigator-determined reasons that made participation in the clinical trial inappropriate.

Primary outcomes {#Sec7}
----------------

The primary outcome was medication adherence. Dose-taking adherence, dose-frequency adherence, dose-interval adherence, and drug holidays were assessed based on the smart pill box data in the ICT-based centralized monitoring group, and based on the drug administration diary in the ambulatory follow-up group. Dose-taking adherence was calculated as (the number of pills taken over a certain time period/the number of pills prescribed over the same period) × 100%. Dose-frequency adherence was calculated as (the number of days of correct daily dosing over a certain time period/the number of days in the same period) × 100%. Dose-interval adherence was calculated as (the number of correct dosing intervals over a certain time period/the number of days in the same period) × 100%. A correct dosing interval was defined with a margin of ±25%. In this trial, the medication was to be taken twice daily, with a 12-h dosing interval. Thus, the allowed dosing interval ranged from 9 to 15 h. A drug holidays was calculated as (the number of days without taking the medication/the number of days in the same period) × 100%.

Secondary outcomes {#Sec8}
------------------

The secondary outcomes included transplant outcomes and patient satisfaction with the system. Trough levels of tacrolimus and mycophenolic acid, coefficient of variation (CV) of drug levels, and eGFR were measured at 4, 8, 12, 16, 20, and 24 weeks of follow-up. To determine within-patient variability in immunosuppressant trough levels, the CV (%) was calculated as (the standard deviation/mean trough level of the immunosuppressant) × 100 \[[@CR11]\]. Panel-reactive antibody (PRA) was assessed at baseline and at 24 weeks. At 12 weeks, we measured serum BK virus, which is a well-known etiologic agent of viral infection in KTRs \[[@CR12]\]. To evaluate clinical outcome, we analyzed the development of biopsy-proven acute rejection (BPAR) and death-censored graft loss (DCGL) during follow-up. At 4 and 24 weeks, a patient satisfaction questionnaire was administered in the ICT-based centralized clinical trial monitoring group to determine whether the patients were satisfied with the system. This questionnaire is presented in additional file [1](#MOESM1){ref-type="media"}. This questionnaire was conducted because patient reported outcomes, including satisfaction with the system, are important, and it is important to ensure that patients are willing to use the system in the future.

Statistical analysis {#Sec9}
--------------------

Between-group differences were tested by independent sample *t*-tests and chi-squared tests, as appropriate. The inter-group difference in immunosuppressant adherence was assessed using the *t*-test, and intra-group variation was analyzed with the paired *t*-test. Statistical analyses were performed using the SAS system for Windows, version 9.2 (SAS Institute Inc., Cary, NC). A *p* value of \< 0.05 was considered statistically significant.

Results {#Sec10}
=======

Study participants {#Sec11}
------------------

Figure [1](#Fig1){ref-type="fig"} shows patient inclusion in a flowchart. A total of 114 KTRs were randomized 1:1 into the intervention group (*n* = 57) or control group (*n* = 57). After excluding patients who withdrew consent or dropped out, the final analyses included 51 KTRs in the intervention group and 54 in the control group. Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of the included patients. The mean age was 49.9 years in the intervention group, and 49.0 years in the control group. Males comprised 60.8% of the intervention group, and 53.7% of the control group. Living donor KT had been performed in 47.1% of the intervention group, and 35.2% of the control group. The mean eGFR was 69.7 in the intervention group, and 74.3 in the control group. Fig. 1Flow of participants inclusion. A total of 114 KTRs were randomized 1:1 into the intervention group (*n* = 57) or control group (*n* = 57). After excluding patients who withdrew consent or dropped out, the final analyses included 51 KTRs in the intervention group and 54 in the control groupTable 1Baseline characteristicsIntervention (*n* = 51)Control (*n* = 54)Age, years49.9 ± 10.049.0 ± 12.2Male, *n* (%)31 (60. 8)29 (53.7)Smoking, *n* (%) Non-smoker39 (76.5)48 (88.9) Ex-smoker8 (15.7)6 (11.1) Current smoker4 (7.8)0 (0)Time after KT, months30.7 ± 19.815.7 ± 9.5Primary renal disease, *n* (%) Diabetes13 (25.5)13 (24.1) Non-diabetes38 (74.5)41 (75.9)Donor age, years46.0 ± 12.645.3 ± 14.8Donor male, *n* (%)25 (49.0)31 (59.6)Donor type, *n* (%) Living24 (47.1)19 (35.2) Deceased27 (52.9)35 (64.8)Number of HLA mismatch Total3.5 ± 1.93.0 ± 1.6 DR1.1 ± 0.81.0 ± 0.6PRA \> 10%, *n* (%)11 (21.6)13 (24.1)Baseline laboratory data Creatinine, mg/dL1.1 ± 0.41.1 ± 0.3 eGFR, mL/min/1.73 m^2^69.7 ± 19.074.3 ± 22.2Values are shown as mean ± standard deviation or number (%)*eGFR* estimated glomerular filtration rate, *HLA* Human leukocyte antigen, *KT* Kidney transplantation, *PRA* Panel-reactive antibody

Adherence {#Sec12}
---------

Figure [2](#Fig2){ref-type="fig"} shows dose-taking adherence, dose-frequency adherence, dose-interval adherence, and drug holidays at each period. Patients in both groups had \> 98% adherence throughout the entire study period. The two groups did not significantly differ in adherence, including dosing, time, and drug holidays. Fig. 2Dose-taking adherence, dose-frequency adherence, dose-interval adherence, and drug holidays at each period. The two patient groups did not significantly differ in adherence in terms of dosing, time, or drug holidays

Transplant outcomes between the intervention and control groups {#Sec13}
---------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} presents transplant outcomes. The intervention and control groups did not significantly differ in the tacrolimus trough levels (5.3 ± 1.2 vs. 5.0 ± 1.2, *p* = 0.282), tacrolimus CV (23.9 ± 13.5 vs. 25.1 ± 11.4, *p* = 0.645), mycophenolic acid trough levels (2.8 ± 1.6 vs. 2.6 ± 1.3, *p* = 0.600), mycophenolic acid CV (37.9 ± 17.3 vs. 38.9 ± 19.4, *p* = 0.783), or renal allograft function at 4 weeks (67.8 ± 18.2 vs. 71.4 ± 21.8, *p* = 0.365) or at 24 weeks (65.2 ± 18.9 vs. 70.2 ± 21.0, *p* = 0.203). Moreover, there was no significant between-group difference in the incidence of development of de novo anti-HLA antibodies (5.9% vs. 14.8%, *p* = 0.135). Neither BPAR nor DCGL occurred. Table 2Transplant outcomes in the intervention and control groupsIntervention (*n* = 51)Control (*n* = 54)*p* valueDrug levels TAC trough level, ng/mL5.3 ± 1.25.0 ± 1.20.282 TAC CV^a^23.9 ± 13.525.1 ± 11.40.645 MPA trough level, μg/mL2.8 ± 1.62.6 ± 1.30.600 MPA CV^a^37.9 ± 17.338.9 ± 19.40.783eGFR 4 weeks67.8 ± 18.271.4 ± 21.80.365 8 weeks67.9 ± 19.771.3 ± 19.20.373 12 weeks66.7 ± 19.471.3 ± 21.60.262 16 weeks67.6 ± 17.472.4 ± 21.90.213 20 weeks66.3 ± 18.071.6 ± 21.80.182 24 weeks65.2 ± 18.970.2 ± 21.00.203Number of events, *n* (%) De novo anti-HLA antibodies3 (5.9)8 (14.8)0.135 BK viremia1 (2.0)1 (1.9)1.000 BPAR---- DCGL----Values are shown as mean ± standard deviation or number (%)*BPAR* Biopsy-proven acute rejection, *CV* Coefficient of variation, *DCGL* Death-censored graft loss, *eGFR* estimated glomerular filtration rate, *HLA* Human leukocyte antigen, *MPA* Mycophenolic acid, *TAC* Tacrolimus^a^CV = (standard deviation/mean) × 100%

Transplant outcomes according to feedback generation {#Sec14}
----------------------------------------------------

In the intervention group, a total of 25 significant alarms and feedback messages were generated for 13 KTRs: 17 for missed doses, 6 for dosage errors, and 2 for dosing time errors. The following measurements in the intervention group did not significantly differ according to the number of feedback messages generated: tacrolimus trough levels (5.1 ± 1.2 vs. 5.3 ± 1.1, *p* = 0.574) tacrolimus CV (29.4 ± 16.3 vs. 22.1 ± 12.0, *p* = 0.155), mycophenolic acid trough levels (2.4 ± 1.0 vs. 2.9 ± 1.8, *p* = 0.332), mycophenolic acid CV (36.6 ± 24.8 vs. 38.3 ± 14.3, *p* = 0.754), renal allograft function at 4 weeks (71.5 ± 21.9 vs. 66.6 ± 16.9, *p* = 0.474) and at 24 weeks (65.7 ± 23.5 vs. 65.0 ± 17.4, 0.928), and the incidence of development of de novo anti-HLA antibodies (7.7% vs 5.3%, *p* = 0.555) (Table [3](#Tab3){ref-type="table"}). Figure [3](#Fig3){ref-type="fig"} shows an example of adherence data in the intervention group as presented in the electronic case report form system. This report allows medical staff to check on the patient's medication use, dosing time, and dosage. Table 3Transplant outcomes of the intervention group according to the number of feedback messages generatedFeedback ≥1 (*n* = 13)No feedback (*n* = 38)*p* valueDrug levels TAC trough level, ng/mL5.1 ± 1.25.3 ± 1.10.574 TAC CV^a^29.4 ± 16.322.1 ± 12.00.155 MPA trough level, μg/mL2.4 ± 1.02.9 ± 1.80.332 MPA CV^a^36.6 ± 24.838.3 ± 14.30.754eGFR 4 weeks71.5 ± 21.966.6 ± 16.90.474 8 weeks69.8 ± 22.767.3 ± 18.80.720 12 weeks66.4 ± 21.066.8 ± 19.10.946 16 weeks66.6 ± 19.467.9 ± 16.90.829 20 weeks66.9 ± 22.266.1 ± 16.60.914 24 weeks65.7 ± 23.565.0 ± 17.40.928Number of events, *n* (%) De novo anti-HLA antibodies1 (7.7)2 (5.3)0.748 BK viremia0 (0)1 (2.6)0.555 BPAR---- DCGL----Values are shown as mean ± standard deviation or number (%)*BPAR* Biopsy-proven acute rejection, *CV* Coefficient of variation, *DCGL* Death-censored graft loss, *eGFR* estimated glomerular filtration rate, *HLA* Human leukocyte antigen, *MPA* Mycophenolic acid, *TAC* Tacrolimus^a^CV = (standard deviation/mean) × 100%Fig. 3An example of adherence data in the intervention group as presented in the electronic case report form system. **a** Monthly data for one subject. **b** Monthly data for all subjects

System satisfaction {#Sec15}
-------------------

Table [4](#Tab4){ref-type="table"} shows the general information regarding patients who completed the ICT-based clinical trial system satisfaction questionnaire. Of these patients, 50.0% were in their 50s, 57.1% were men, and 76.2% lived in large cities. All patients used a smartphone, and they searched for health information (information about symptoms, medications, etc.) on the Internet or through wireless communications with a mean frequency of 1.8 times per week. Table 4General information about patients who completed the ICT-based clinical trial system satisfaction questionnaireAge, *n* (%) 20s2 (4.8) 30s2 (4.8) 40s9 (21.4) 50s21 (50.0) 60s or above8 (19.1)Male, *n* (%)24 (57.1)Education level, *n* (%) Elementary school3 (7.1) Middle school6 (14.3) High school23 (54.8) University9 (21.4) Above university1 (2.4)Area of residence, *n* (%) Large city (metropolitan city)32 (76.2) Small- to medium-sized city6 (14.3) Agricultural and fishing village4 (9.2)Smartphone use, *n* (%)42 (100)Weekly frequency of searching health information (symptoms, medications, etc.) on the Internet or though wireless communications1.8 ± 1.7Occupation, *n* (%) Self-employment11 (26.2) Employee7 (16.7) Agricultural and livestock industry workers2 (4.8) Monk or Pastor1 (2.4) Student1 (2.4) Housewife11 (26.2) Not employed9 (21.4)Values are shown as mean ± standard deviation or number (%)

Table [5](#Tab5){ref-type="table"} shows the patients' satisfaction with the ICT-based clinical trial system. The overall satisfaction with the system was above the median score, and significantly increased across the study period. The patients gave generally positive assessments of the system's convenience, safety, and accuracy, and generally responded positively to the idea of using the system to participate in future clinical trials. Table 5ICT-based clinical trial system satisfaction questionnaire scoresVisit 2Visit 7*p* valueAre you satisfied with the system, overall?3.6 ± 1.03.9 ± 0.70.012Was the system convenient to use?3.6 ± 0.93.8 ± 0.80.294Was it safe to use the system in the clinical trial?4.1 ± 0.44.1 ± 0.70.767Did use of the system reduce the duration of the trips made to participate in this clinical trial?3.4 ± 0.83.4 ± 0.80.499Did use of the system reduce the inconvenience associated with transportation?3.3 ± 0.83.4 ± 0.80.618Were the researchers able to more accurately assess your condition by using the system?4.0 ± 0.73.9 ± 0.70.710Did the devices included in the system (fingerprint sensor, home monitoring devices, gateway/smartphone apps, modem, etc.) provide reliable measurements?3.8 ± 0.83.9 ± 0.70.844Were the aforementioned devices easy to use?3.9 ± 0.93.9 ± 0.80.872Are you satisfied with the education regarding directions and precautions for using the aforementioned devices?4.2 ± 0.74.1 ± 0.70.183Are you satisfied with how the researchers handled errors that arose from the aforementioned devices?4.3 ± 0.84.3 ± 0.80.200Total scores38.2 ± 5.838.8 ± 5.50.622If the ICT-based centralized monitoring system is introduced into this clinical trial,Will you consistently participate in this clinical trial using the ICT-based centralized monitoring system?3.9 ± 1.03.7 ± 0.80.323Will you participate in this clinical trial even if it takes place at a hospital located farther away from your home owing to the availability of the system at that location?3.3 ± 1.23.1 ± 1.00.648Was this clinical trial using the system helpful for the management of your health?3.9 ± 0.93.9 ± 0.90.578Will this clinical trial using the system positively contribute to your quality of life?3.7 ± 1.03.7 ± 0.80.660Would you recommend a clinical trial using this system to others?3.6 ± 1.13.8 ± 0.80.263Do you think clinical trials using the system may lead to any losses or damage associated with personal medical information leakage?3.5 ± 1.03.9 ± 0.90.054Do you think it will become more difficult to use medical services owing to technical issues associated with the system?3.7 ± 1.03.8 ± 0.80.893Do you think technical issues associated with the system will give rise to medical accidents?4.1 ± 0.83.9 ± 0.90.130Total scores29.6 ± 5.429.8 ± 4.20.932Values are shown as mean ± standard deviationEach domain is rated on a scale from 1 to 5, with higher scores reflecting better satisfaction

Discussion {#Sec16}
==========

In this randomized clinical trial, we found that Korean KTRs already showed high adherence in terms of dosing and timing. The ICT-based centralized monitoring system did not significantly improve adherence to immunosuppressive medications or transplant outcomes in this population. However, the KTRs expressed overall high satisfaction with the ICT-based centralized monitoring system, and this satisfaction significantly improved across the study period. Participants gave an overall positive assessment of the system's convenience, safety, and accuracy. Although this system did not maximize mediation adherence or enhance transplant outcomes in KTRs due to the already high baseline adherence, the high satisfaction indicates that the system could be successfully applied in future clinical trials targeting other disease groups with impaired adherence.

Previous studies have assessed the effects of technology-based adherence-promoting interventions---including the use of electronically monitored drug-dispensing devices or mobile phone applications with feedback (including alarms, text messages, telephone calls, e-mails, or face-to-face meeting)---and have demonstrated that such interventions are associated with higher adherence among KTRs or other organ transplant recipients \[[@CR7]--[@CR9], [@CR13]--[@CR16]\]. Table [6](#Tab6){ref-type="table"} summarizes recent studies evaluating technology-based adherence-promoting interventions in KTRs. Henriksson et al. tested the use of an electronic medication dispenser for 1 year to improve adherence among KTRs (40 intervention patients, 40 control patients), and reported that the intervention was associated with high adherence \[[@CR9]\]. However, unlike our current study, that prior study did not measure adherence in the control group, and did not determine different aspects of adherence, such as dose-taking adherence, dose-frequency adherence, and dose-interval adherence. Reese et al. examined the use of electronic medication monitoring and reminders (including alarms, texts, telephone calls, and/or e-mails) either alone or in combination with provider notification for 6 months among KTRs (40 patients with reminders, 39 with reminders plus provider notification, and 38 control patients), and found that the intervention resulted in significantly better medication dose-taking adherence \[[@CR8]\]. While our current study used only text messages and pill box alarms, Reese et al. may have made participants more comfortable with the system by enabling them to choose from customized reminders. In the study of Foster et al., KTRs (81 intervention patients, 88 control patients) received reminders (including text messages, e-mails, and/or visual cues for dose reminders) and had face-to-face meetings with a coach at 3-month intervals over 12 months. Their results demonstrated that the intervention led to significantly better medication dose-taking adherence and dose-frequency adherence \[[@CR7]\]. Unlike our present study, that previous study included face-to-face feedback from a coach, which might contribute to different results. On limitation that is shared between previous studies and our present study is that the electronic pill bottles and the smart pill box only measure opening, but do not confirm actual pill ingestion. Table 6Studies evaluating technology-based adherence-promoting interventions among kidney transplant recipientsAuthors, Year \[Ref.\]Study design and sampleInterventionDurationAdherenceResults for adherence and clinical outcomesAdvantageDisadvantagesHenriksson et al., 2016 \[[@CR9]\]RCT*n* = 80 (40 intervention, 40 control)Device: Electronic medication dispenserFeedback: emitted visual and audible alerts12 monthsDose-taking adherenceNo significant differences in tacrolimus trough levels, risk of BPAR, or creatinine levelsNo adherence information in the control groupMeasured only dispenser opening, not actual pill ingestionReese et al., 2017 \[[@CR8]\]RCT*n* = 117 (40 reminders, 39 reminders plus provider notification, 38 control)Device: Electronic medication monitor and reminders either alone or in combination with provider notificationFeedback: alarms, texts, telephone calls, and/or e-mails6 monthsDose-taking adherenceSignificantly better adherence with reminders plus provider notification and with reminders alone compared to in the control groupNo significant difference in tacrolimus trough levelsVarious feedback methodsMeasured only dispenser opening, not actual pill ingestionFoster et al., 2018 \[[@CR7]\]RCT*N* = 169 (81 intervention, 88 control)Device: Electronic medication monitor and face-to-face educationFeedback: text messages, e-mails, and/or visual cue dose reminders12 monthsDose-taking adherence and dose-frequency adherenceIntervention group had significantly better adherence than the control groupNo significant difference in the standard deviation of tacrolimus trough levelsVarious feedback methodsMeasured only dispenser opening, not actual pill ingestionJung et al., 2020 \[the current study\]RCT*N* = 105 (51 intervention, 54 control)Device: Smart pill boxFeedback: text messages, pill box alarms6 monthsDose-taking adherence, dose-frequency adherence, and dose-interval adherenceNo significant difference in adherence, tacrolimus and mycophenolic acid trough levels, coefficient of variation of drug levels, and risk of the development of de novo anti-HLA antibodiesThe ICT-based centralized monitoring system can be linked to not only smart pill box but also blood sugar meter, electrocardiogram, spirometry, and INR meterMeasured only box opening, not actual pill ingestion*HLA* Human leukocyte antigen, *ICT* Information and communication technology, *RCT* Randomized controlled trial

With regards to the effects of interventions on transplant outcomes, previous studies have reported conflicting results. We hypothesized that the ICT-based centralized monitoring system could improve medication adherence in KTRs, ultimately inducing stable drug concentrations and thus reducing the development of de novo anti-HLA antibodies, viral infection, and BPAR. Contrary to our expectations, drug adherence, tacrolimus and MPA trough concentrations, drug level variability, and the incidences of development of de novo anti-HLA antibodies, BK viremia, and BPAR did not significantly differ between the ICT-based centralized monitoring group and the control group, or within the intervention group between patients with versus without feedback generation. Compared with previous studies, the KTRs in our present study exhibited considerably higher adherence of 99--100%. Therefore, there was little-to-no room for improvement based on feedback generated from the ICT-based centralized monitoring system. Consequently, we did not observe superior transplant outcomes in the ICT-based centralized monitoring group compared with the control group, or in the patients with versus without feedback generation within the intervention group.

Although we did not find that the monitoring system led to improved adherence due to the already high baseline adherence in Korean KTRs, this study has several strengths and the results have clinical implications. First, to our knowledge, this is the first study to investigate the adherence of Korean KTRs with continuous use of an ICT-based centralized monitoring system. Moreover, it is the first clinical study to provide data regarding medication adherence among Korean KTRs. The higher adherence observed in Korean KTRs compared to in KTRs in other countries could be partly due to the national health insurance coverage system for transplant recipients in South Korea. Out present data suggest that the proportion of non-adherence leading to antibody-mediated rejection may differ among countries \[[@CR1]\], and that the causes of renal allograft loss may also differ. This indicates that different and additional immunological strategies may be required to improve renal allograft survival in different countries. Second, the overall satisfaction with the system was higher than neutral, even though most users were in their 50s or older. This suggests that the ICT-based centralized monitoring system could be applied to other diseases, such as recipients of other organ transplants, or patients with hypertension, diabetes, chronic kidney disease, cardiovascular disease, human immunodeficiency virus infection, dementia, and tuberculosis. Moreover, the high satisfaction with the ICT-based clinical trial could pave the way for establishing an ICT-based centralized monitoring system for future clinical trials. Further system validation will be necessary to expand the use of this monitoring system in future clinical trials.

Conclusions {#Sec17}
===========

In conclusion, in our present study, the ICT-based centralized monitoring system did not improve mediation adherence or transplant outcomes in Korean KTRs due to the already high baseline adherence. However, we found high patient satisfaction with the system in terms of convenience, safety, and accuracy. This suggests that the ICT-based centralized monitoring system could be successfully used in future clinical trials targeting other disease groups with impaired adherence and in which medication adherence critical to the course of treatment.

Advantages and disadvantages {#Sec18}
----------------------------

Through this clinical trial, we identified the following advantages and disadvantages of the ICT-based centralized monitoring system. First, this system enabled us to receive real-time information on adherence collected through the smart pill box, check this information using an electronic case report form system, and provide patients with real-time feedback regarding dose, frequency, and interval. This enabled medical staff to identify patients' patterns and exact times of taking medicines, and helped them understand the levels of immunosuppressive agents in the outpatient clinic. Second, the ICT-based centralized monitoring system could be linked to not only the smart pill box but also to a blood sugar meter, electrocardiogram, spirometry, and INR meter. Therefore, a strength of this system is that it can be successfully used in other diseases that require constant monitoring due to severe fluctuations in symptoms or results. Third, like recent studies that have introduced systems that collect current information and predict future trends \[[@CR17]--[@CR20]\], once our adherence-related information is accumulated, it will also be available to predict future patterns of adherence in KTRs. Forth, some patients experienced technical problems, such as failed fingerprint recognition or incorrect reminders while they were out. However, these technical issues were all resolved early in the study. Fifth, in areas with inconsistent Internet communication, there may be problems with data transmission.
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